OCUGEN INC (OCGN) Stock Price, Quote, News and Overview
NASDAQ:OCGN - Nasdaq - US67577C1053 - Common Stock - Currency: USD
OCGN Quote, Performance and Key Statistics
1.09
0 (0%)
The current stock price of OCGN is 1.09 USD. In the past month the price increased by 34.57%. In the past year, price decreased by -18.05%.
OCGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.06 | 327.65B | ||
| AMGN | AMGEN INC | 13.95 | 155.74B | ||
| GILD | GILEAD SCIENCES INC | 13.95 | 134.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.59 | 55.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.72B | ||
| ARGX | ARGENX SE - ADR | 93.55 | 32.85B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.47 | 27.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.10B | ||
| NTRA | NATERA INC | N/A | 23.35B | ||
| BIIB | BIOGEN INC | 8 | 18.54B | ||
| INSM | INSMED INC | N/A | 18.12B |
Related stock screener links
About OCGN
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Company Info
OCUGEN INC
11 Great Valley Parkway
Malvern PENNSYLVANIA 19355 US
CEO: Shankar Musunuri
Employees: 95
Phone: 14843284701
OCUGEN INC / OCGN FAQ
What is the stock price of OCUGEN INC today?
The current stock price of OCGN is 1.09 USD.
What is the ticker symbol for OCUGEN INC stock?
The exchange symbol of OCUGEN INC is OCGN and it is listed on the Nasdaq exchange.
On which exchange is OCGN stock listed?
OCGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OCUGEN INC stock?
10 analysts have analysed OCGN and the average price target is 6.63 USD. This implies a price increase of 508.26% is expected in the next year compared to the current price of 1.09. Check the OCUGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OCUGEN INC worth?
OCUGEN INC (OCGN) has a market capitalization of 318.31M USD. This makes OCGN a Small Cap stock.
How many employees does OCUGEN INC have?
OCUGEN INC (OCGN) currently has 95 employees.
What are the support and resistance levels for OCUGEN INC (OCGN) stock?
OCUGEN INC (OCGN) has a support level at 1.08 and a resistance level at 1.13. Check the full technical report for a detailed analysis of OCGN support and resistance levels.
Is OCUGEN INC (OCGN) expected to grow?
The Revenue of OCUGEN INC (OCGN) is expected to decline by -79.42% in the next year. Check the estimates tab for more information on the OCGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OCUGEN INC (OCGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OCGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OCGN, evaluating the profitability, health, valuation and growth aspects
- OCUGEN INC (OCGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OCUGEN INC (OCGN) Sales and EPS estimates to see what analysts future expectations are.
- OCUGEN INC (OCGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OCUGEN INC (OCGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- OCUGEN INC (OCGN) Stock Chart to make your own analysis
- OCUGEN INC (OCGN) Latest news and press-releases to stay up to date.
Does OCUGEN INC (OCGN) stock pay dividends?
OCGN does not pay a dividend.
When does OCUGEN INC (OCGN) report earnings?
OCUGEN INC (OCGN) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of OCUGEN INC (OCGN)?
OCUGEN INC (OCGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
What is the Short Interest ratio of OCUGEN INC (OCGN) stock?
The outstanding short interest for OCUGEN INC (OCGN) is 23.83% of its float. Check the ownership tab for more information on the OCGN short interest.
OCGN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OCGN. When comparing the yearly performance of all stocks, OCGN is one of the better performing stocks in the market, outperforming 90.54% of all stocks.
OCGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCGN. OCGN may be in some trouble as it scores bad on both profitability and health.
OCGN Financial Highlights
Over the last trailing twelve months OCGN reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 13.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.67% | ||
| ROE | -436.12% | ||
| Debt/Equity | 1.74 |
OCGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to OCGN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -32.87% and a revenue growth -79.42% for OCGN